SENSOME
13.1.2020 08:02:12 CET | Business Wire | Press release
Sensome, the company pioneering the connected medical device revolution with the world’s smallest biological tissue sensor, announced today the successful completion of a 9 million dollar financing round from its historical investors (Kurma Partners, Idinvest Partners, BNP Paribas Développement, Paris-Saclay Seed Fund) joined by Asahi Intecc Co., Ltd. from Japan, a world leader in guidewire technology. The funds raised will serve to test the clinical performance of Sensome’s first product Clotild® , a proprietary connected guidewire, and get it ready for market. Sensome and Asahi also agreed to a two-year development plan to design a new connected guidewire for the treatment of ischemic stroke, combining Sensome’s proprietary micro-sensor and Asahi’s CHIKAI guidewire.
Acute ischemic stroke, the leading cause of long-term disability, can now be treated by removing the clot blocking the brain blood vessel using mechanical thrombectomy devices. These devices are guided from the groin over a wire. Sensome transforms these guidewires with its tissue sensor to help physicians remove the clot on the first attempt, which is currently achieved in only one out of three cases and greatly improves patient prognosis.
“The future of interventional therapies depends on accessing the right information at the right time. We have developed the technology to empower medical devices with the required connectivity and data, be it in stroke or other medical fields,” said Franz Bozsak, CEO and co-founder of Sensome, and added, “The partnership with Asahi will demonstrate how Sensome’s sensor technology can be integrated seamlessly into any high-performance medical device.”
“The smart guidewire for stroke aims to gather and utilize significant data regarding clot, contributing to better treatment outcomes in intravascular acute ischemic stroke. An easy-to-use high-performance guidewire with onboard sensor will allow the physician to know more about the clot without significant disruption to the current procedure,” explained Masahiko Miyata, CEO of Asahi Intecc. “The combination of Sensome's sophisticated sensor technology and Asahi's guidewire technology is highly synergetic. Asahi is confident that this collaboration will yield a revolutionary smart guidewire with excellent mechanical performance and unique capability.”
About Sensome www.sensome.com
About ASAHI INTECC CO., LTD. www.asahi-intecc.co.jp
About Kurma Partners www.kurmapartners.com
About BNP Paribas Développement www.bnpparibasdeveloppement.com
About Paris-Saclay Seed Fund www.seedfund.parissaclay.com
About Idinvest Partners www.idinvest.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200112005017/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
DEWA Organises Second Agentic AI Retreat at Al Shera’a, World’s Tallest, Largest and Smartest Net‑Positive Government Building12.6.2026 17:08:00 CEST | Press release
HE Saeed Mohammed Al Tayer, MD & CEO of Dubai Electricity and Water Authority (DEWA),has emphasised that DEWA deploys the latest Agentic AI technologies, in line with the vision to enhance its leading role and reinforce Dubai’s position as the city of the future. He made these remarks during the Agentic AI Executive Retreat DEWA organised at Al Shera’a, its new headquarters, which is the world’s tallest, largest and smartest net-positive government building. The event was attended by the executive leadership team and key stakeholders in digital transformation and artificial intelligence (AI), as well as representatives from SAP and McKinsey. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612633834/en/ DEWA organises second Agentic AI Retreat at Al Shera’a, world’s tallest, largest and smartest net positive government building (Photo: AETOSWire) In his speech, Al Tayer said that DEWA is guided by directives from the wise l
BeOne Medicines’ Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA 202612.6.2026 12:00:00 CEST | Press release
Tacabrutideg (BGB-16673, BTK degrader) showed durable responses in heavily pretreated R/R CLL and BTK inhibitor–naïve patients, signaling potential for earlier lines of treatmentBRUKINSA plus sonrotoclax (ZS) delivered deep, durable responses and high uMRD rates across TN CLL and R/R MCL and CLL, reinforcing its potential as an all-oral, fixed-duration treatment BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its foundational hematology franchise at the 2026 European Hematology Association (EHA) Congress in Stockholm. Updated results from tacabrutideg (BGB-16673), a potential best-in-class Bruton’s tyrosine kinase (BTK) degrader, demonstrated durable responses in pretreated relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), with early activity also seen in BTK inhibitor–naïve patients. These data are complemented by results from the all-oral combination of BRUKINSA® (zanubru
Cyviz: Microsoft’s Immersive Approach to Collaboration12.6.2026 09:00:00 CEST | Press release
At Microsoft’s Innovation Hub in Amsterdam, immersive technology is used to enable co-creation rather than one-way presentations. In the company’s Immersive Suite, customers, data experts, and technology specialists come together in a shared environment to address complex challenges more effectively. Watch Video Case Study >> This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612831180/en/ Watch Video Case Study >> https://www.cyviz.com/case-studies/microsoft-immersive-suite/ As business and technology environments grow more complex, establishing shared understanding across disciplines has become critical. The Immersive Suite is designed for active collaboration, where visual narratives, data, and technical content are explored interactively. This allows participants to test scenarios, align perspectives, and move more efficiently from discussion to decision. “We deliberately work with familiar tools like PowerPoint. That all
LTM Launches AI 1000 to Develop the Next Generation of Forward Deployed Engineers12.6.2026 08:14:00 CEST | Press release
LTM, the Business Creativity partner to the world’s largest enterprises, today announced AI 1000, a strategic workforce transformation initiative anchored by a dedicated Center of Excellence (CoE). The program will develop a pool of 1,000+ AI-certified engineers, including Forward Deployed Engineers (FDEs), to help enterprises adopt, deploy, and scale AI. The launch comes amid a major shift in enterprise tech talent. The FDE — among the fastest-growing roles in the AI ecosystem — combines the technical knowledge of LLMs and domain SLMs with business understanding to turn ideas into quantifiable ROI accretive outcomes and to drive client adoption. AI 1000 is LTM’s structured response to this shift: it provides the training, platforms, and governed career frameworks to develop FDEs at scale. AI 1000 takes an end-to-end approach to talent development via a four-stage model: Identify, Enable, Deploy, and Govern. It starts by identifying high-potential engineers using a proprietary AI Readi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom